Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. (Q30368814)

21 June 2017

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. (English)

1 reference

21 June 2017

phase III clinical trial

0 references

0 references

1 reference

13

Frank von Sonnenburg

0 references

W Ripley Ballou

16

object named as

W Ripley Ballou

1 reference

21 June 2017

14

Mamadou Dramé

1 reference

21 June 2017

Jan Hendrik Richardus

5

object named as

Jan Hendrik Richardus

1 reference

21 June 2017

2

José-María Bayas

1 reference

21 June 2017

6

Magda Campins

1 reference

21 June 2017

Hans C Rümke

1

1 reference

21 June 2017

José-Ramón de Juanes

3

1 reference

21 June 2017

Covadonga Caso

4

1 reference

21 June 2017

Lars Rombo

7

1 reference

21 June 2017

Xavier Duval

8

1 reference

21 June 2017

Viktor Romanenko

9

1 reference

21 June 2017

Tino F Schwarz

10

1 reference

21 June 2017

Rustem Fassakhov

11

1 reference

21 June 2017

Francisco Abad-Santos

12

1 reference

21 June 2017

Roland Sänger

15

1 reference

21 June 2017

language of work or name

English

0 references

publication date

27 March 2008

1 reference

21 June 2017

1 reference

21 June 2017

26

1 reference

21 June 2017

19

1 reference

21 June 2017

2378-2388

1 reference

H5N1 outbreaks and enzootic influenza

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

H5N1 influenza--continuing evolution and spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Pre- or post-pandemic influenza vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Detecting human-to-human transmission of avian influenza A (H5N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Scientific barriers to developing vaccines against avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Selection of influenza vaccine strains and developing pandemic vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Vaccines against avian influenza--a race against time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Development of vaccines against influenza H5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Rapid licensure of a new, inactivated influenza vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Fluarix, inactivated split-virus influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.068

10.1016/J.VACCINE.2008.02.068

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference